The Company’s priority program, ENMD-2076, has completed multiple Phase 1 oncology studies and is completing a multi-center Phase 2 study in ovarian cancer, and is currently enrolling in a dual-center Phase 2 study in triple-negative breast cancer. In addition to ENMD-2076 for oncology, we have a Phase 1 candidate, Panzem® (2ME2), for the treatment of rheumatoid arthritis, which also demonstrated positive preclinical results for multiple sclerosis.
ENMD-2076 offers promising and unique opportunities for development and commercialization for the following reasons:
Multiple Mechanisms of Action
Diseases such as cancer employ multiple strategies to survive involving various cellular signaling pathways that promote their transformation and growth. Cancer cells can rapidly evade drugs that are highly specific for a target within one of these pathways through the development of resistance mechanisms. If more than one of these redundant signaling pathways can be interrupted at once, then the chance for resistance to develop is greatly reduced. ENMD-2076 acts by attacking cancer cells through multiple pathways that promote the formation and replication of tumor cells, while also interrupting the formation of blood vessels that nourish and sustain tumor growth. EntreMed has pursued oncology indications that could provide proof-of-concept data to support the design of pivotal trials.
While the Company’s clinical efforts continue to focus on oncology, EntreMed believes that other diseases where angiogenesis plays a role in pathology represent future opportunities.
EntreMed’s drug candidates will be easy to use as compared to other modes of drug administration. The Company is focusing specifically on drugs that can be administered orally.
Intellectual Property Position
All EntreMed drug candidates are backed by strong international intellectual property rights, including issued or pending composition, method and use patents.